If you have been reading about Drug affinity complex and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-07-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
== Hybrid closed-loop systems == Hybrid closed-loop (HCL) systems, also known as automated insulin delivery (AID) systems, are medical technologies designed to assist individuals with diabetes in regulating blood glucose levels. These systems integrate a continuous glucose monitor (CGM), an insulin pump, and a control algorithm to automatically adjust basal insulin delivery and, in some systems, administer correction boluses. The term "hybrid" refers to the fact that while the system automates many aspects of insulin dosing, users are still required to manually input carbohydrate intake and manually administer bolus doses for meals. HCL systems aim to maintain glucose levels within a target range and reduce the frequency and severity of hypoglycemia and hyperglycemia. Research and development of HCL systems began in the early 2000s, with efforts such as the Advanced Insulin Infusion Using a Control Loop (ADICOL) project. A 2008 clinical trial by Weinzimer et al. demonstrated that hybrid closed-loop therapy significantly improved overnight glucose control compared to conventional insulin delivery. The first HCL system to receive regulatory approval was the MiniMed 670G (Medtronic) in 2016. Since then, other systems—including the MiniMed 770G and 780G, Tandem t:slim X2 with Control-IQ, and CamAPS FX—have also been introduced, employing various algorithmic strategies such as model predictive control (MPC), proportional-integral-derivative (PID) control, and fuzzy logic.
==== Transport through the nuclear membrane ==== The actin sequence does not contain a nuclear localization signal. The small size of actin (about 43 kDa) allows it to enter the nucleus by passive diffusion. The import of actin into the nucleus (probably in a complex with cofilin) is facilitated by the import protein importin 9. Low levels of actin in the nucleus seems to be important, because actin has two nuclear export signals (NES) in its sequence. Microinjected actin is quickly removed from the nucleus to the cytoplasm. Actin is exported at least in two ways, through exportin 1 and exportin 6. Specific modifications, such as SUMOylation, allows for nuclear actin retention. A mutation preventing SUMOylation causes rapid export of beta actin from the nucleus.
=== Pharmacokinetics === Oral tacrolimus is slowly absorbed in the gastrointestinal tract, with a total bioavailability of 20 to 25% (but with variations from 5 to 67%) and highest blood plasma concentrations (Cmax) reached after one to three hours. Taking the drug together with a meal, especially one rich in fat, slows down resorption and reduces bioavailability. In the blood, tacrolimus is mainly bound to erythrocytes; only 5% are found in the plasma, of which more than 98.8% are bound to plasma proteins. The substance is metabolized in the liver, mainly via CYP3A, and in the intestinal wall. All metabolites found in the circulation are inactive. Biological half-life varies widely and seems to be higher for healthy persons (43 hours on average) than for patients with liver transplants (12 hours) or kidney transplants (16 hours), due to differences in clearance. Tacrolimus is predominantly eliminated via the faeces in form of its metabolites. When applied locally on eczema, tacrolimus has little to no bioavailability.
=== 1985 === February 6: The Reagan Doctrine commits the United States of America to supporting anti-Communist insurgencies in the Third World. March 10: General Secretary of the Communist Party of the Soviet Union Konstantin Chernenko dies. March 11: Mikhail Gorbachev becomes leader of the Soviet Union. March 15: Military rule ends in Brazil. March 24, 1985: Major Arthur D. Nicholson, a US Army Military Intelligence officer is shot to death by a Soviet sentry in East Germany. He is listed as the last US casualty in the Cold War. April 11: Enver Hoxha dies. Ramiz Alia takes over as First Secretary of the Party of Labor of Albania, becoming the de facto leader of Albania. April 22: The Trial of the Juntas convenes to prosecute the members of the National Reorganization Process (the military junta that governed Argentina from 1976 to 1983) for war crimes and crimes against humanity committed during its existence. May 20: John Anthony Walker is arrested by the FBI. August 6: Coinciding with the 40th anniversary of the atomic bombings of Hiroshima and Nagasaki, the Soviet Union begins what it has announced is a 5-month unilateral moratorium on the testing of nuclear weapons. The Reagan administration dismisses the dramatic move as nothing more than propaganda and refuses to follow suit. Gorbachev declares several extensions, but the United States fails to reciprocate, and the moratorium comes to an end on February 5, 1987. November 7: Crisis of Sigonella, diplomatic conflict between Italy and the United States.
Sources: en.wikipedia.org
=== Viscosity === Semen viscosity can be estimated by gently aspirating the sample into a wide-bore plastic disposable pipette, allowing the semen to drop by gravity and observing the length of any thread. High viscosity can interfere with determination of sperm motility, sperm concentration and other analysis.
=== Metabolism: 20th century – present === One of the most prolific of these modern biochemists was Hans Krebs who made huge contributions to the study of metabolism. Krebs was a student of extremely important Otto Warburg, and wrote a biography of Warburg by that title in which he presents Warburg as being educated to do for biological chemistry what Fischer did for organic chemistry. Which he did. Krebs discovered the urea cycle and later, working with Hans Kornberg, the citric acid cycle and the glyoxylate cycle. These discoveries led to Krebs being awarded the Nobel Prize in physiology in 1953, which was shared with the German biochemist Fritz Albert Lipmann who also codiscovered the essential cofactor coenzyme A.
== Use and effects == Noribogaine is the major active metabolite of the oneirogen ibogaine and is thought to be primarily though not exclusively responsible for its effects. In contrast to ibogaine, noribogaine has been limitedly evaluated in humans. It was noted in 2007 that administration of noribogaine to humans had not yet been reported. In 2015 and 2016 however, two clinical studies of noribogaine were published. It was tested at relatively low doses of 3 to 180 mg in these studies. At these doses, no hallucinations, dream-like states, or other hallucinogenic effects were reported. Similarly, it produced no μ-opioid receptor agonistic pharmacodynamic effects, such as pupil constriction or analgesia. At higher doses, in the area of 400 to 1,000 mg or more, ibogaine has been reported to produce hallucinogenic effects.
== Connection and treatment of autism == Effective therapies to manage autism remain scarce. According to the exorphin theory of autism, an increase in the levels of exorphin is linked to symptoms of autism. Based on this concept, experiments have attempted to reduce the symptoms of autism by using large amounts of protease to break down exorphins before they are absorbed. Experiments have also attempted to enhance and utilize enzymes existing in the gut to break down exorphins in a similar fashion, since the production of exorphins within the gut is inevitable.
For weight loss to be permanent, changes in diet and lifestyle must be permanent as well. There is evidence that counseling or exercise alone do not result in weight loss, whereas dieting alone results in meaningful long-term weight loss, and a combination of dieting and exercise provides the best results. Meal replacements, orlistat, a very-low-calorie diet, and primary care intensive medical interventions can also support meaningful weight loss.
Sources: en.wikipedia.org
==== Blood donation ==== Frequent blood donors are also at risk for developing iron deficiency anemia. When whole blood is donated, approximately 200 mg of iron is lost from the body. The blood bank screens people for anemia before drawing blood for donation. If the patient has anemia, blood is not drawn. Less iron is lost if the person is donating platelets or white blood cells.
=== Ma–Me === Alan MacDiarmid (1927–2007), American-New Zealand chemist who discovered conductive polymers, 2000 Nobel Prize in Chemistry Carolina Henriette Mac Gillavry (1904–1993), Dutch chemist and crystallographer known for discoveries on the use of diffraction in crystallography Roderick MacKinnon (born 1956), American biophsicist known for work on ion channels; 2003 Nobel Prize in Chemistry Pierre Macquer (1718–1784), French chemist known for Dictionnaire de chymie Rudolph A. Marcus (1923–2026), Canadian chemist known for work on the theory of electron transfer reactions; 1992 Nobel Prize in Chemistry Jacob A. Marinsky (1918–2005), American chemist, co-discovered the element promethium Jean Charles Galissard de Marignac (1817–1894), Swiss chemist who discovered ytterbium and co-discovered gadolinium Vladimir Vasilevich Markovnikov (1838–1904), Russian chemist known for Markovnikov's rule describing addition reactions of hydrogen halides and alkenes Tobin J. Marks (born 1944), American inorganic chemist and materials scientist known for work in polymerization catalysts Alan G.
=== TV documentaries === ARTE (French/German TV Channel): Since 2018, ARTE has aired documentaries on the world of fascia, featuring Robert Schleip. SWR (German TV Channel): Documentaries aired on October 25, 2021, and September 10, 2020, explored the "fascia boom" and included contributions from Schleip.
Social determinants such as neighborhood disadvantage, immigration status, lack of social support, social isolation, and access to health services play an important role in myocardial infarction risk and survival. Studies have shown that low socioeconomic status is associated with an increased risk of poorer survival. There are well-documented disparities in myocardial infarction survival by socioeconomic status, race, education, and census-tract-level poverty. Race: In the U.S. African Americans have a greater burden of myocardial infarction and other cardiovascular events. On a population level, there is a higher overall prevalence of risk factors that are unrecognized and therefore not treated, which places these individuals at a greater likelihood of experiencing adverse outcomes and therefore potentially higher morbidity and mortality. Similarly, South Asians (including South Asians that have migrated to other countries around the world) experience higher rates of acute myocardial infarctions at younger ages, which can be largely explained by a higher prevalence of risk factors at younger ages. Socioeconomic status: Among individuals who live in the low-socioeconomic (SES) areas, which is close to 25% of the US population, myocardial infarctions (MIs) occurred twice as often compared with people who lived in higher SES areas.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.